These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 33393507)

  • 1. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.
    von Locquenghien M; Rozalén C; Celià-Terrassa T
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of interferon dependent and independent signaling pathways: Implications in cancer.
    Spada S; Ganguly A
    Int Rev Cell Mol Biol; 2024; 389():153-162. PubMed ID: 39396846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferons, immunity and cancer immunoediting.
    Dunn GP; Koebel CM; Schreiber RD
    Nat Rev Immunol; 2006 Nov; 6(11):836-48. PubMed ID: 17063185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering interferons for cancer immunotherapy.
    Lim J; Lee HK
    Biomed Pharmacother; 2024 Oct; 179():117426. PubMed ID: 39243429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor inherent interferons: Impact on immune reactivity and immunotherapy.
    Brockwell NK; Parker BS
    Cytokine; 2019 Jun; 118():42-47. PubMed ID: 29681426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications.
    Hargadon KM
    Br J Dermatol; 2021 Dec; 185(6):1095-1104. PubMed ID: 34185875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferons: role in cancer therapy.
    Abdolvahab MH; Darvishi B; Zarei M; Majidzadeh-A K; Farahmand L
    Immunotherapy; 2020 Aug; 12(11):833-855. PubMed ID: 32635782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-edged effects of interferons on the regulation of cancer-immunity cycle.
    Zhang X; Wang S; Zhu Y; Zhang M; Zhao Y; Yan Z; Wang Q; Li X
    Oncoimmunology; 2021; 10(1):1929005. PubMed ID: 34262796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Radiation with Immunotherapy: The University of Pennsylvania Experience.
    Luo LY; O'Hara MH; Mitchell TC; Vonderheide RH; Wherry EJ; Minn AJ; Maity A
    Semin Radiat Oncol; 2020 Apr; 30(2):173-180. PubMed ID: 32381296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting innate sensing in the tumor microenvironment to improve immunotherapy.
    Liu Z; Han C; Fu YX
    Cell Mol Immunol; 2020 Jan; 17(1):13-26. PubMed ID: 31844141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy.
    Lin X; Huang R; Huang Y; Wang K; Li H; Bao Y; Wu C; Zhang Y; Tian X; Wang X
    Int J Nanomedicine; 2021; 16():1889-1899. PubMed ID: 33707944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I and II interferons toward ideal vaccine and immunotherapy.
    Temizoz B; Ishii KJ
    Expert Rev Vaccines; 2021 May; 20(5):527-544. PubMed ID: 33993812
    [No Abstract]   [Full Text] [Related]  

  • 13. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
    Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
    Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological and clinical basis for molecular studies of interferons.
    Pang KR; Wu JJ; Huang DB; Tyring SK; Baron S
    Methods Mol Med; 2005; 116():1-23. PubMed ID: 16007741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opposing Roles of Type I Interferons in Cancer Immunity.
    Boukhaled GM; Harding S; Brooks DG
    Annu Rev Pathol; 2021 Jan; 16():167-198. PubMed ID: 33264572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies.
    Ajina R; Zahavi DJ; Zhang YW; Weiner LM
    Semin Cancer Biol; 2020 Oct; 65():28-37. PubMed ID: 31866479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I interferons and dendritic cells in cancer immunotherapy.
    Sprooten J; Agostinis P; Garg AD
    Int Rev Cell Mol Biol; 2019; 348():217-262. PubMed ID: 31810554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of interferons and other cytokines in the regulation of the immune response.
    Belardelli F
    APMIS; 1995 Mar; 103(3):161-79. PubMed ID: 7538771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.